

AMENDMENTS TO THE CLAIMS

Claim 1 (Currently amended): A stable, liquid formulation comprising (a) an anti-IgE antibody that is rhuMAbE25 in an amount of 120 to 260 mg/ml, (b) arginine-HCl in an amount of 100 to 200 mM, (c) histidine in an amount of 10 to 100 mM, (d) polysorbate in an amount of 0.01 to 0.1%, where the formulation further has a pH ranging from 5.5 to [[7.0]] 6.0, a kinematic viscosity of about 50 cs or less, an osmolarity ranging from 200 mOsm/kg to 450 mOsm/kg and a turbidity of 0.30 O.D. or less mean absorbance as measured by a 1-cm quartz cuvette using an Hewlett-Packard 8453 diode array spectrophotometer at 340-360 nm.

Claim 2 (Canceled)

Claim 3 (Previously presented): The formulation of Claim 1, wherein the concentration of antibody ranges from 150 mg/ml to 260 mg/ml.

Claim 4 (Previously presented): The formulation of Claim 1, wherein the concentration of antibody ranges from 180 mg/ml to 260 mg/ml.

Claim 5 (Previously presented): The formulation of Claim 1, wherein the concentration of antibody ranges from 200 mg/ml to 260 mg/ml.

Claim 6 (Previously presented): The formulation of Claim 1, wherein the concentration of antibody is about 150 mg/ml.

Claim 7 (original): The formulation of Claim 1, wherein the osmolarity ranges from 250 mOsm/kg to 350 mOsm/kg.

Claim 8 (Previously presented): The formulation of Claim 1, wherein the concentration of arginine-HCl is 200 mM.

Claims 9 - 19 (Canceled)

Claim 20 (Currently amended): A stable, liquid formulation comprising (a) an anti-IgE antibody that is rhuMAbE25 in an amount of about 150 mg/ml, (b) arginine-HCl in an amount of 200 mM, (c) histidine in an amount of 20 mM, (d) polysorbate in an amount of ~~0.02%~~ 0.01% to 0.1%, where the formulation further has a pH of 6.0 and a turbidity of 0.30 O.D. or less mean absorbance as measured by a 1-cm quartz cuvette using an Hewlett-Packard 8453 diode array spectrophotometer at 340-360 nm.

Claim 21 (Canceled)

Claim 22 (Previously presented): An article of manufacture comprising a container enclosing the formulation of Claims 1 or 20.

Claim 23 (Original): The article of manufacture of Claim 22, wherein the container is a syringe.

Claim 24 (Original): The article of manufacture of Claim 23, wherein the syringe is further contained within an injection device.

Claim 25 (Original): The article of manufacture of Claim 24, wherein the injection device is an auto-injector.

Claim 26 - 50 (Canceled)

Claim 51 (New): The formulation of Claim 1, wherein the concentration of arginine-HCl ranges from 150 to 200 mM.

Claim 52 (New): The formulation of Claim 1, wherein the concentration of arginine-HCl ranges from 180 to 200 mM.